Are Peptides Legal in 2026? The FDA Reclassification Explained

The legal status of peptides in the United States is changing. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 previously banned peptides would be reclassified from Category 2 (banned from compounding) back to Category 1 (legal to compound). This includes popular peptides like BPC-157, Thymosin Alpha-1, AOD-9604, and others.

That announcement now has a concrete next step. A Federal Register notice published April 16, 2026 scheduled the FDA's Pharmacy Compounding Advisory Committee (PCAC) to vote on July 23–24, 2026 on the first batch of peptides — and the agenda names 7 specific substances, not the full 14. Knowing exactly which peptides are on that vote (and which popular ones are not) matters, because much of the coverage online conflates RFK Jr.'s broad intent with what the committee is actually deciding this summer.

This article explains what the reclassification means, which peptides are affected, what the July 23–24 vote actually covers, and how it relates to FDA-approved drugs like semaglutide (Wegovy) and investigational drugs like retatrutide.

What Happened: The RFK Peptide Announcement

On the Joe Rogan Experience podcast (aired February 28, 2026), HHS Secretary RFK Jr. announced his intention to reverse the Biden-era FDA ban on compounding certain peptides. Key points from the announcement:

• Approximately 14 of 19 restricted peptides will move from Category 2 to Category 1
• He called the original ban "illegal," arguing the FDA lacked the required safety signal to justify restrictions
• He argued the ban pushed consumers to the unregulated gray market: "We created the gray market"
• The reclassification would go through the FDA's normal advisory-committee process rather than take effect overnight
• 5 peptides with weaker safety profiles will remain restricted

The announcement was a statement of intent, not an instant rule change. The mechanism is the FDA's Pharmacy Compounding Advisory Committee (PCAC), which reviews bulk substances and votes on whether to recommend moving them between categories. As of June 2026, no peptide has been formally moved back to Category 1 yet — the first batch goes to a PCAC vote on July 23–24, 2026 (see below).

What Category 1 and Category 2 Mean

The FDA uses a category system to classify bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act:

Category 1 does NOT mean FDA-approved. It means a licensed compounding pharmacy can legally prepare the substance with a valid prescription from a healthcare provider. The substance has not undergone the full clinical trial process required for FDA drug approval. No insurance coverage, no standardized dosing guidelines, and no FDA-level quality oversight.

Which Peptides Are Affected

The 14 Peptides Expected to Return to Legal Compounding

Based on the announcement and available analysis, these peptides are expected to move from Category 2 to Category 1:

Five of these (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank) were already removed from Category 2 in September 2024 and referred to the Pharmacy Compounding Advisory Committee (PCAC) for review.

The 5 Peptides Expected to Remain Restricted

The exact final list has not been officially published. Some uncertainty remains about which 5 will stay restricted.

The July 2026 PCAC Vote: What's Actually on the Agenda

RFK Jr.'s "14 peptides" figure describes his stated intent. It is not the list the FDA is voting on this summer. The Federal Register notice published April 16, 2026 put 7 peptides in front of the Pharmacy Compounding Advisory Committee for its July 23–24, 2026 meeting. These are the substances that could actually move to Category 1 first:

A second PCAC meeting, expected before the end of February 2027, is slated to review 5 additional peptides.

Popular peptides that are NOT on the July vote

This is where most online coverage gets it wrong — including a widely shared thread from a cardiologist that listed several of these as being reviewed in July. They are not on the July 23–24 agenda:

If you see a protocol described as "about to be legal in July," check it against the 7-peptide list above. A peptide can be part of RFK Jr.'s broader 14 and still not be on the committee's July ballot.

Reclassification is not FDA approval

Even if the committee votes yes and the FDA follows the recommendation, these peptides become Category 1 bulk substances — legal for a licensed compounding pharmacy to prepare with a valid prescription. They do not become FDA-approved drugs. There are still no large randomized human trials behind the recovery and longevity uses driving demand, no standardized dosing, and no insurance coverage. The vote changes the legal sourcing pathway, not the strength of the evidence.

The Five Legal Tiers of Peptide Status

Not all peptides have the same legal standing. Here is how the different categories work in practice:

Tier 1: FDA-Approved Drugs

These peptides completed full clinical trials and received FDA marketing authorization. Legal to prescribe, covered by some insurance plans.

Tier 2: Legal Compounded Peptides (Category 1)

These can be prepared by licensed compounding pharmacies with a valid prescription. They are not FDA-approved drugs — no standardized dosing, no insurance coverage, and quality depends on the individual pharmacy.

This is the category that the reclassified peptides would enter.

Tier 3: Banned Compounds (Category 2)

These are prohibited from compounding. Any pharmacy offering them is operating illegally. This is the category that the 14 peptides are expected to leave.

Tier 4: Investigational Drugs

Retatrutide falls in this category. It is in Phase 3 clinical trials and cannot be compounded, purchased, or prescribed outside of an FDA-authorized clinical trial. The FDA issued warning letters in September 2025 to companies selling retatrutide. For legitimate access, see Retatrutide Cost & How to Get It.

Tier 5: Gray Market "Research Chemicals"

Peptides sold online labeled "for research purposes only." Purchasing them is not illegal for consumers, but they are not regulated by the FDA, quality varies widely, and marketing them for human use is illegal. The RFK reclassification aims to move consumers away from this tier and into supervised medical care.

How This Relates to GLP-1 Drugs

The peptide reclassification is a separate regulatory action from the GLP-1 compounding debate. Key distinctions:

• Semaglutide and tirzepatide are NOT among the 19 peptides being reclassified. They are FDA-approved drugs with a completely different regulatory pathway.
• The FDA declared the semaglutide shortage resolved in February 2025, ending the legal basis for compounding pharmacies to produce copies. Compounding of semaglutide has been wound down.
• Retatrutide is NOT affected by the reclassification. It is an investigational drug that cannot be compounded under any circumstance.

However, some reclassified peptides are marketed as weight loss alternatives:

• AOD-9604 — a growth hormone fragment studied for fat metabolism (failed its Phase 2b trial)
• MOTS-C — a mitochondrial peptide with no human weight loss clinical evidence
• CJC-1295 + Ipamorelin — growth hormone secretagogues with zero human weight loss trials

These are not equivalent to GLP-1 drugs. For a full evidence comparison, see Peptides vs GLP-1 for Weight Loss.

Timeline of the Peptide Ban

What This Means for Consumers

What You Can Do

• Get FDA-approved GLP-1 drugs (semaglutide, tirzepatide) with a valid prescription from any licensed pharmacy
• Enroll in clinical trials for investigational drugs like retatrutide through ClinicalTrials.gov
• Watch the July 23–24, 2026 PCAC vote before starting anything new — it determines which of the first 7 peptides actually move to Category 1, and when
• Once reclassification is formalized: obtain Category 1 peptides from licensed compounding pharmacies with a valid prescription from a healthcare provider

What You Cannot Do

• Obtain compounded Category 2 peptides — until the reclassification is formally published, they remain banned
• Get compounded semaglutide — the shortage has been resolved and compounding is no longer permitted
• Purchase retatrutide for human use — it is an investigational drug available only through clinical trials
• Rely on "research use only" peptides for medical treatment — these are unregulated products

Frequently Asked Questions

Sources

• FDA. (2026). Meeting of the Pharmacy Compounding Advisory Committee, July 23–24, 2026. fda.gov.
• BioPharma Dive. (2026). FDA moves toward easing restrictions on certain peptides. biopharmadive.com.
• Gizmodo. (2026). RFK Jr. Tells Joe Rogan He's About to Unleash 14 Banned Peptides. gizmodo.com.
• FDA. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. fda.gov.
• Reed Smith LLP. (2024). FDA removes certain peptide bulk drug substances from Category 2. Lexology.
• DJ Holt Law. (2026). Regulatory Alert: The Legal Status of BPC-157. djholtlaw.com.
• FierceHealthcare. (2025). FDA declares semaglutide shortage over. fiercehealthcare.com.
• Health Law Alliance. (2026). FDA Targets GLP-1 and Peptide Compounding. healthlawalliance.com.